Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Change in Account Payables (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Change in Account Payables for 5 consecutive years, with -$183000.0 as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 69.04% to -$183000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $826000.0 through Dec 2025, down 18.3% year-over-year, with the annual reading at $826000.0 for FY2025, 18.3% down from the prior year.
  • Change in Account Payables hit -$183000.0 in Q4 2025 for Krystal Biotech, up from -$4.0 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $4.1 million in Q2 2025 to a low of -$4.0 million in Q3 2025.
  • Historically, Change in Account Payables has averaged $59700.0 across 5 years, with a median of $99000.0 in 2023.
  • Biggest five-year swings in Change in Account Payables: soared 579.44% in 2024 and later tumbled 4517.58% in 2025.
  • Year by year, Change in Account Payables stood at $937000.0 in 2021, then crashed by 200.11% to -$938000.0 in 2022, then skyrocketed by 76.33% to -$222000.0 in 2023, then crashed by 166.22% to -$591000.0 in 2024, then surged by 69.04% to -$183000.0 in 2025.
  • Business Quant data shows Change in Account Payables for KRYS at -$183000.0 in Q4 2025, -$4.0 million in Q3 2025, and $4.1 million in Q2 2025.